- Home
- UFCS vs GERN Comparison
UFCS vs GERN Comparison
Compare UFCS & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UFCS
- GERN
- Stock Information
- Founded
- UFCS 1946
- GERN 1990
- Country
- UFCS United States
- GERN United States
- Employees
- UFCS N/A
- GERN N/A
- Industry
- UFCS Property-Casualty Insurers
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- UFCS Finance
- GERN Health Care
- Exchange
- UFCS Nasdaq
- GERN Nasdaq
- Market Cap
- UFCS 713.9M
- GERN 700.6M
- IPO Year
- UFCS N/A
- GERN 1996
- Fundamental
- Price
- UFCS $30.66
- GERN $1.45
- Analyst Decision
- UFCS Buy
- GERN Buy
- Analyst Count
- UFCS 2
- GERN 8
- Target Price
- UFCS $30.50
- GERN $3.71
- AVG Volume (30 Days)
- UFCS 143.2K
- GERN 12.3M
- Earning Date
- UFCS 08-05-2025
- GERN 08-06-2025
- Dividend Yield
- UFCS 2.09%
- GERN N/A
- EPS Growth
- UFCS 143.32
- GERN N/A
- EPS
- UFCS 3.51
- GERN N/A
- Revenue
- UFCS $1,322,727,000.00
- GERN $164,447,000.00
- Revenue This Year
- UFCS $11.31
- GERN $159.14
- Revenue Next Year
- UFCS $10.61
- GERN $52.76
- P/E Ratio
- UFCS $8.75
- GERN N/A
- Revenue Growth
- UFCS 14.18
- GERN 11877.20
- 52 Week Low
- UFCS $19.19
- GERN $1.09
- 52 Week High
- UFCS $31.70
- GERN $4.83
- Technical
- Relative Strength Index (RSI)
- UFCS 69.60
- GERN 60.22
- Support Level
- UFCS $25.79
- GERN $1.26
- Resistance Level
- UFCS $31.15
- GERN $1.43
- Average True Range (ATR)
- UFCS 0.80
- GERN 0.09
- MACD
- UFCS 0.42
- GERN 0.03
- Stochastic Oscillator
- UFCS 90.76
- GERN 87.80
About UFCS United Fire Group Inc.
United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.